Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that the leadership team will ho

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that members of its executive ma

Coiled Therapeutics plc (AIM: COIL / OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces its interim results for the

Successful Enrolment Completed Across Two Cohorts of New AO-252 Formulation

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, is pleased to announce the appointment of

First Patient Dosed with Optimised Lipid-Based Formulation of AO-252

Lipid-Based Softgel Designed to Optimise Drug Exposure Ahead of Dose Expansion

Coiled Therapeutics (AIM: COIL) (OTCQB: COTFX), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that ahead of its presentation at the Proactive One2One Investor For

Seasoned biotech and capital markets leader joins the Board

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that the Company's Chairman Sotirios Stergiopoulos will present at t

Coiled Therapeutics (AIM: COIL, OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that it will be presenting at the Proactive One2One Investor Forum (t

Coiled Therapeutics (AIM:COIL) (OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces it has granted 6,200,000 share options ("Options") over the Company's

Leading Oncology Drug Developers Join Coiled Therapeutics Medical Advisory Board to Support AO-252 Clinical Development

Appointment of Professor Ozgur Sahin as Scientific Advisor

Commencement of Trading on US OTCQB Venture Market

Coiled Therapeutics to Showcase AO-252 at Prestigious Endless Frontier Labs 2026 Event

Coiled Therapeutics plc (AIM: COIL), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces the appointment of Dr Andrew Dean as Non-Executive Director with immediate effe

Coiled Therapeutics plc (AIM: COIL), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, formerly Roquefort Therapeutics plc, announces its audited results for the year ended 31

Presentation at the 18th Annual World Cancer Congress

Enhanced Efficacy Signal and Strategic Transition to Dose Expansion

NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON THE LONDON STOCK EXCHANGE

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that following the General Meeting held earlier today at which shareholders approved the acquisition of the exclusive worldwide licence

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has agreed to extend the Longstop Dates (defined below) in relation to the binding share purchase agreement ("Lyramid SPA") for the s

Roquefort will be renamed Coiled Therapeutics plc ("Coiled") upon the completion of the acquisition of the AO-252 Licence from A2A Pharmaceuticals, Inc.

Proposed Acquisition and Conditional Fundraise of £8.5 million

Transaction Update & Intention to delist from the Main Market

Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, announces that a new research note regarding the Company's proposed transaction with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc.,

Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, announces that the binding exclusive license agreement with Coiled Therapeutics, Inc.

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that the Company has received notices, in two tranches, to convert a total face value of £80,000 convertible loan notes (the "CLNs") res

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that further to the Company's announcement earlier today confirming that the record date for determining entitlement to the Unlisted Red

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that, following the announcement on 3 November 2025 regarding the proposed issue of new unlisted redeemable non-voting shares ("Unlisted

Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, is pleased to announce that further to the announcements made on 8 September, 16 October and 3 November 2025, the Company has entered into a b

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd ("Pleiades") in return for up to US$25 millio

Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, is pleased to announce that it has raised funds of £300,000, with £200,000 by way of advance subscription agreements ("Advance Subscriptions")